
The rare disease drug developer pulled in $145m through a round led by Pivotal BioVenture Partners and backed by Mitsui and Fidelity.
GV and Illumina Ventures returned to reinvest in cellular therapy developer SQZ Biotechnologies, which has now raised at least $166m to date.
Johnson & Johnson Innovation – JJDC was among the investors in an $11.7m round for blood sealant technology developer Gatt Technologies.
Holmusk, developer of a behavioural healthcare evidence platform, has completed a $21.5m round co-led by corporate venturing unit Optum Ventures.
The AstraZeneca cancer drug spinoff floated above its range in an upsized initial public offering and now has a market cap topping $2bn.
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Genscript Biotech’s subsidiary Legend Biotech, which agreed to an investment worth nearly $151m from Eli Lilly and Johnson & Johnson last month, has filed to go public.
GV and Tyson Ventures invested in an $18m funding round for Clear Labs that has now raised $62m altogether from backers also including Dentsu and Tencent.
Continental Grain-backed RNA material producer GreenLight Biosciences is hoping to supply ingredients for RNA-based coronavirus vaccines after securing $17m in funding.
Intel Capital has invested at least $132m in 12 companies so far this year and is on its way to putting between $300m and $500m into startups by the end of 2020.